Company: BDRX
Filing Date: 2025-11-03
Form Type: 424B3
Source: 0001214659-25-015743
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-03
Form: 424B3
Chunk 2
---
 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing
for the month of November 2025 is:

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: November 3, 2025 | Biodexa Pharmaceuticals PLC 
 By:                         | /s/ Stephen Stamp                                   |
|:-----------------------|:----------------------------|:----------------------------------------------------|
|                        |                             | Stephen Stamp                                       |
|                        |                             | Chief Executive Officer and Chief Financial Officer |

Exhibit 99.1

November 3, 2025

<div align='center'>Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP

First European patient expected to be enrolled in 4Q 2025

Addressable US - European Market Put at $7 Billion</div>

Biodexa Pharmaceuticals PLC (“Biodexa”
or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products
for the treatment of diseases with unmet medical needs, announced the approval of a Clinical Trial Application (CTA) by the European Medicines
Agency (EMA) of its pivotal Phase 3 Serenta trial in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that,
if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of much of the
gastrointestinal tract.

A CTA is the formal regulatory submission required
to obtain approval to begin a clinical trial in Europe and is similar to the Investigational New Drug (IND) application process in the
United States. The CTA permits the Serenta trial to proceed in Europe, initially covering clinical sites in Denmark, Germany